News stories about Fluidigm (NASDAQ:FLDM) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fluidigm earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.7382061134891 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
Get Fluidigm alerts:
Analysts Anticipate Fluidigm Co. (FLDM) to Post -$0.41 Earnings Per Share (americanbankingnews.com) Fluidigm Co. (FLDM) Insider Levin Capital Strategies, L.P. Purchases 20,029 Shares (americanbankingnews.com) Fluidigm Introduces a Lower-Cost Workflow for Full-LengthSingle-Cell mRNA Sequencing on C1 (finance.yahoo.com) Fluidigm (FLDM) to Release Quarterly Earnings on Thursday (americanbankingnews.com)
Fluidigm traded down $0.12, reaching $6.28, during mid-day trading on Wednesday, Marketbeat reports. 88,300 shares of the company’s stock were exchanged, compared to its average volume of 186,896. Fluidigm has a one year low of $2.52 and a one year high of $8.38. The firm has a market cap of $235.05 million, a price-to-earnings ratio of -5.28 and a beta of 3.03. The company has a debt-to-equity ratio of 3.38, a quick ratio of 1.95 and a current ratio of 2.40.
Fluidigm (NASDAQ:FLDM) last released its quarterly earnings results on Thursday, May 3rd. The medical research company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.07. Fluidigm had a negative net margin of 55.66% and a negative return on equity of 98.85%. The business had revenue of $25.25 million for the quarter, compared to analyst estimates of $25.40 million. sell-side analysts anticipate that Fluidigm will post -0.9 EPS for the current year.
A number of equities analysts recently commented on the stock. Zacks Investment Research lowered shares of Fluidigm from a “buy” rating to a “hold” rating in a research report on Wednesday, July 4th. ValuEngine raised shares of Fluidigm from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd.
In other Fluidigm news, insider Levin Capital Strategies, L.P. purchased 20,029 shares of the stock in a transaction that occurred on Friday, July 27th. The shares were acquired at an average cost of $6.14 per share, with a total value of $122,978.06. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have purchased 560,319 shares of company stock worth $2,932,728. 2.20% of the stock is owned by insiders.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Read More: Find a Trading Strategy That Works